Navigation Links
Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer

ASCO Oral Presentation Reports Significantly More Patients Treated with Taxotere(R)-Based Chemotherapy Regimen Survived at Least Three Years

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Taxotere(R) (docetaxel) Injection Concentrate-based chemotherapy (Taxotere plus prednisone) maintained long-term efficacy as a treatment for advanced (metastatic) hormone-resistant prostate cancer patients, according to the three-year updated results of the landmark TAX 327 study. Results of the international multi-center phase III trial were reported in an oral presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The TAX 327 data show that among patients with metastatic hormone- resistant prostate cancer, significantly more of those treated with Taxotere(R) 75mg/m2 combined with prednisone 5 mg once every three weeks survived at least three years, than those treated with anti-cancer antibiotic mitoxantrone combined with prednisone. Patients treated with the Taxotere(R) regimen lived a median of three months longer (19.3 months versus 16.3 months, p=0.006) and had a 21% lower risk of dying (HR=17.6-21.3). These results are consistent with results published in 2004 in the New England Journal of Medicine and document the maintenance of the survival benefit previously reported in patients treated with the Taxotere-based therapy.

"The results confirm docetaxel's survival benefit in patients with metastatic hormone resistant prostate cancer," said study author Dominik R. Berthold, Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada. "Prolonged survival is extremely important for these patients and docetaxel is the only chemotherapeutic agent to demonstrate a survival benefit in this setting."

Original TAX 327 Analysis Showed Improved Survival

The TAX 327 study was initiated in 2000 to evaluate long-term survival among men with metastatic h
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
3. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
4. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
5. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
6. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
7. Media Advisory: ACC Updated Schedule
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
(Date:8/29/2014)... September yoga month was created by ... and its health benefits. To support this Ekhart Yoga ... "Yoga Month Challenge" , This 4 week guided online ... experienced yogis practice yoga regularly from their own home. ... ' is suitable for all levels, and the dynamic ...
(Date:8/29/2014)... 29, 2014 RBS Reputation Management has brought ... The service is to help those individuals and organizations ... on Scam Book. The service would push down the ranking ... Book complaints fully invisible on Google. , RBS Reputation ... On being asked how company can provide guarantee of results ...
(Date:8/29/2014)... week, the Fed reported an increase in industrial ... to 0.4% while manufacturing output progressed to 1.0%. , ... since February this year. Capacity use has increased by more ... an increase that could be attributed to the boost in ... is a measure of slack across the industries. , Output ...
(Date:8/29/2014)... 2014 Ethane Web Technologies, an ISO ... new service named HTML web design. , The HTML ... tailoring the service, Ethane Web Technologies did extensive research ... company has done its best efforts to make sure ... deliver outstanding results to clients. The company uses ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
Breaking Medicine News(10 mins):Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Ethane Web Technologies Launches a New Web Design Service 2
... Highlights ... ... In recognition of Gynecologic Cancer Awareness Month, Planned Parenthood of the Rocky Mountains is ... screenings and treatments to help save their lives., , ,"We see firsthand at our ...
... , , ARLINGTON, Va., ... and Human Services Office of Inspector General (OIG) ignored the ... complex rehab, to seniors and people with disabilities who require ... Medicare Program: Supplier Acquisition Costs and Services" and dated August ...
... WASHINGTON, Sept. 3 Speaker Nancy Pelosi released the following statement ... "Any real change requires the inclusion of a strong public ... option is not included, it would be a major victory for the ... that a public option will keep the insurance companies honest. If someone ...
... VALLEY NATIONAL PARK, STOVE PIPE WELLS, Calif., Sept. 3 Jeff ... , will hike 40 miles per day through California,s Death Valley ... September 5, 2009, Sekerak hikes from Stove Pipe Wells to a ... to demonstrate the superior level of fitness attained through his program, ...
... , BROOMFIELD, Colo., Sept. 3 Embla(R) ... will acquire Covidien,s Sleep Diagnostic business. This includes the sleep diagnostic ... the transaction were not disclosed. Completion of the sale is subject ... entity will form the world,s largest company to focus entirely on ...
... YORK, Sept. 3 As millions of teens head back to school, ... , Teens are at a greater risk of than any ... lack of experience. Many of those crashes could be avoided with proper ... produces free driver education programs. , , NRSF spokesperson ...
Cached Medicine News:Health News:Planned Parenthood Stresses Importance of Regular Checkups During Gynecologic Cancer Awareness Month 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:One Man's Answer to the Health Care Crisis: Develop Extreme Fitness 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: